Clinical Study Details

AusTrials is now conducting the REIMAGINE-4 Research Project. The purpose of the research project is to compare a potential new weight loss treatment called CagriSema when compared with Tirzepatide (also known by its commercial name Mounjaro®) in people with Type 2 Diabetes.

CAGRISEMA IS NOT REGISTERED OR AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC

The research project consists of three periods:

• Screening Period: 3 weeks (approx.).
• Treatment Period: 68 weeks.
• Follow-up Period: 6 weeks.

The research project involves 15 clinic visits and 7 scheduled follow up phone calls. During the Treatment Period, participants will be allocated into one of two groups, each group receiving either the study treatment CagriSema, or the comparator Trizepatide. There is no placebo control group.

You may be eligible to participate in this research project if you:

• Are 18 years of age or older
• Have a BMI of ≥ 30 kg/m2
• Have been formally diagnosed with Type 2 Diabetes, AND
• Take metformin as part of your regular treatment

Eligible participants will be provided with the corresponding treatment free of charge and will be closely monitored by our medical team throughout the research project. Additionally, they will be compensated for travel related expenses upon completion of each scheduled clinic visit.

Use the links at the bottom of the page to share this study on social media or by email with friends or family who may be interested.

This study is being conducted at the following locations:

• Taringa, Brisbane – QLD
• Sunshine, Melbourne – VIC

If you are interested in participating, please complete the following Expression of Interest Form. Alternatively, you can call us on 1300 190 841 if you wish to speak directly to one of our staff members.